186 related articles for article (PubMed ID: 23504381)
1. Gene expression of catalytic proteasome subunits and resistance toward proteasome inhibition of B lymphocytes from patients with primary sjogren syndrome.
Martinez-Gamboa L; Lesemann K; Kuckelkorn U; Scheffler S; Ghannam K; Hahne M; Gaber-Elsner T; Egerer K; Naumann L; Buttgereit F; Dörner T; Kloetzel PM; Burmester GR; Faustman DL; Feist E
J Rheumatol; 2013 May; 40(5):663-73. PubMed ID: 23504381
[TBL] [Abstract][Full Text] [Related]
2. Immunoproteasome subunit LMP2 expression is deregulated in Sjogren's syndrome but not in other autoimmune disorders.
Krause S; Kuckelkorn U; Dörner T; Burmester GR; Feist E; Kloetzel PM
Ann Rheum Dis; 2006 Aug; 65(8):1021-7. PubMed ID: 16414974
[TBL] [Abstract][Full Text] [Related]
3. Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.
Niewerth D; Kaspers GJ; Assaraf YG; van Meerloo J; Kirk CJ; Anderl J; Blank JL; van de Ven PM; Zweegman S; Jansen G; Cloos J
J Hematol Oncol; 2014 Jan; 7():7. PubMed ID: 24418325
[TBL] [Abstract][Full Text] [Related]
4. Autoimmune reactivity against the 20S-proteasome includes immunosubunits LMP2 (beta1i), MECL1 (beta2i) and LMP7 (beta5i).
Scheffler S; Kuckelkorn U; Egerer K; Dörner T; Reiter K; Soza A; Burmester GR; Feist E
Rheumatology (Oxford); 2008 May; 47(5):622-6. PubMed ID: 18375405
[TBL] [Abstract][Full Text] [Related]
5. Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits.
Busse A; Kraus M; Na IK; Rietz A; Scheibenbogen C; Driessen C; Blau IW; Thiel E; Keilholz U
Cancer; 2008 Feb; 112(3):659-70. PubMed ID: 18181098
[TBL] [Abstract][Full Text] [Related]
6. Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells.
Kraus M; Rückrich T; Reich M; Gogel J; Beck A; Kammer W; Berkers CR; Burg D; Overkleeft H; Ovaa H; Driessen C
Leukemia; 2007 Jan; 21(1):84-92. PubMed ID: 17024115
[TBL] [Abstract][Full Text] [Related]
7. Expression of proteasomal immunosubunit beta1i is dysregulated in inflammatory infiltrates of minor salivary glands in Sjogren's syndrome.
Morawietz L; Martinez-Gamboa L; Scheffler S; Hausdorf G; Dankof A; Kuckelkorn U; Doerner T; Egerer K; Burmester GR; Faustman DL; Feist E
J Rheumatol; 2009 Dec; 36(12):2694-703. PubMed ID: 19833746
[TBL] [Abstract][Full Text] [Related]
8. Tissue-specific up-regulation of the proteasome subunit beta5i (LMP7) in Sjögren's syndrome.
Egerer T; Martinez-Gamboa L; Dankof A; Stuhlmüller B; Dörner T; Krenn V; Egerer K; Rudolph PE; Burmester GR; Feist E
Arthritis Rheum; 2006 May; 54(5):1501-8. PubMed ID: 16646031
[TBL] [Abstract][Full Text] [Related]
9. Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjögren's syndrome and systemic lupus erythematosus.
Sellam J; Miceli-Richard C; Gottenberg JE; Ittah M; Lavie F; Lacabaratz C; Gestermann N; Proust A; Lambotte O; Mariette X
Ann Rheum Dis; 2007 Jun; 66(6):790-7. PubMed ID: 17185325
[TBL] [Abstract][Full Text] [Related]
10. Expression of interferon regulatory factor 1, 3, and 7 in primary Sjögren syndrome.
Zheng L; Yu C; Zhang Z; Yang C; Cai X
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2009 May; 107(5):661-8. PubMed ID: 19426920
[TBL] [Abstract][Full Text] [Related]
11. Alterations of cerebral cortex and hippocampal proteasome subunit expression and function in a traumatic brain injury rat model.
Yao X; Liu J; McCabe JT
J Neurochem; 2008 Jan; 104(2):353-63. PubMed ID: 17944870
[TBL] [Abstract][Full Text] [Related]
12. Methylation profile of the promoter region of IRF5 in primary Sjögren's syndrome.
Gestermann N; Koutero M; Belkhir R; Tost J; Mariette X; Miceli-Richard C
Eur Cytokine Netw; 2012; 23(4):166-72. PubMed ID: 23302156
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma.
Altmann A; Markert A; Askoxylakis V; Schöning T; Jesenofsky R; Eisenhut M; Haberkorn U
J Nucl Med; 2012 Nov; 53(11):1764-71. PubMed ID: 23055533
[TBL] [Abstract][Full Text] [Related]
14. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
[TBL] [Abstract][Full Text] [Related]
15. Complement factor C3a alters proteasome function in human RPE cells and in an animal model of age-related RPE degeneration.
Ramos de Carvalho JE; Klaassen I; Vogels IM; Schipper-Krom S; van Noorden CJ; Reits E; Gorgels TG; Bergen AA; Schlingemann RO
Invest Ophthalmol Vis Sci; 2013 Oct; 54(10):6489-501. PubMed ID: 23982842
[TBL] [Abstract][Full Text] [Related]
16. B-cell activating factor of the tumour necrosis factor family expression in blood monocytes and T cells from patients with primary Sjögren's syndrome.
Lavie F; Miceli-Richard C; Ittah M; Sellam J; Gottenberg JE; Mariette X
Scand J Immunol; 2008 Feb; 67(2):185-92. PubMed ID: 18201372
[TBL] [Abstract][Full Text] [Related]
17. Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer.
de Wilt LH; Jansen G; Assaraf YG; van Meerloo J; Cloos J; Schimmer AD; Chan ET; Kirk CJ; Peters GJ; Kruyt FA
Biochem Pharmacol; 2012 Jan; 83(2):207-17. PubMed ID: 22027222
[TBL] [Abstract][Full Text] [Related]
18. Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells.
Fuchs D; Berges C; Opelz G; Daniel V; Naujokat C
J Cell Biochem; 2008 Jan; 103(1):270-83. PubMed ID: 17516511
[TBL] [Abstract][Full Text] [Related]
19. Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors.
Niewerth D; Franke NE; Jansen G; Assaraf YG; van Meerloo J; Kirk CJ; Degenhardt J; Anderl J; Schimmer AD; Zweegman S; de Haas V; Horton TM; Kaspers GJ; Cloos J
Haematologica; 2013 Dec; 98(12):1896-904. PubMed ID: 24056819
[TBL] [Abstract][Full Text] [Related]
20. Brain-derived neurotrophic factor and nerve growth factor correlate with T-cell activation in primary Sjogren's syndrome.
Fauchais AL; Boumediene A; Lalloue F; Gondran G; Loustaud-Ratti V; Vidal E; Jauberteau MO
Scand J Rheumatol; 2009; 38(1):50-7. PubMed ID: 18830907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
